{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T21:32:59Z","timestamp":1779399179227,"version":"3.53.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,20]]},"DOI":"10.7759\/cureus.71970","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T05:43:12Z","timestamp":1729489392000},"source":"Crossref","is-referenced-by-count":1,"title":["Successful Biological Treatment of a Patient With Psoriasis and HIV"],"prefix":"10.7759","author":[{"given":"Angel  E","family":"Ortegon Blanco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E","family":"Alonzo Canul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"2","author":"Veale DJ","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018, 2:2273-84. 10.1016\/S0140-6736(18)30830-4","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek IM","year":"2017","unstructured":"Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017, 31:205-12. 10.1111\/jdv.13854","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref3","article-title":"Diagnosis and management of psoriasis","volume":"63","author":"Kim WB","year":"2017","unstructured":"Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017, 63:278-85.","journal-title":"Can Fam Physician"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong AW","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. J Am Med Assoc. 2020, 323:1945-60. 10.1001\/jama.2020.4006","journal-title":"J Am Med Assoc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo J","year":"2023","unstructured":"Guo J, Zhang H, Lin W, Lu L, Su J, Chen X. Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023, 8:437. 10.1038\/s41392-023-01655-6","journal-title":"Signal Transduct Target Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123773","article-title":"Cancer immunotherapy and application of nanoparticles in cancers immunotherapy as the delivery of immunotherapeutic agents and as the immunomodulators","volume":"12","author":"Debele TA","year":"2020","unstructured":"Debele TA, Yeh CF, Su WP. Cancer immunotherapy and application of nanoparticles in cancers immunotherapy as the delivery of immunotherapeutic agents and as the immunomodulators. Cancers (Basel). 2020, 12:3773. 10.3390\/cancers12123773","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2016.09.005","article-title":"Opportunistic infections in biological therapy, risk and prevention","volume":"43","author":"Bryant PA","year":"2017","unstructured":"Bryant PA, Baddley JW. Opportunistic infections in biological therapy, risk and prevention. Rheum Dis Clin North Am. 2017, 43:27-41. 10.1016\/j.rdc.2016.09.005","journal-title":"Rheum Dis Clin North Am"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13336","article-title":"Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment","volume":"27","author":"Guttman-Yassky E","year":"2018","unstructured":"Guttman-Yassky E, Krueger JG, Lebwohl MG. Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. Exp Dermatol. 2018, 27:409-17. 10.1111\/exd.13336","journal-title":"Exp Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216095","article-title":"Inflammation and psoriasis: a comprehensive review","volume":"24","author":"Man AM","year":"2023","unstructured":"Man AM, Or\u0103san MS, Hoteiuc OA, Ol\u0103nescu-Vaida-Voevod MC, Mocan T. Inflammation and psoriasis: a comprehensive review. Int J Mol Sci. 2023, 24:16095. 10.3390\/ijms242216095","journal-title":"Int J Mol Sci"},{"key":"ref10","unstructured":"Cosentyx. (2023). https.\/\/www.drugs.com\/cosentyx.html."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1\u00a0year: results from the CLEAR study","volume":"76","author":"Blauvelt A","year":"2017","unstructured":"Blauvelt A, Reich K, Tsai TF, et al.. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1\u00a0year: results from the CLEAR study. J Am Acad Dermatol. 2017, 76:60-9.e9. 10.1016\/j.jaad.2016.08.008","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis-results of two phase 3 trials","volume":"371","author":"Langley RG","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al.. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014, 371:326-38. 10.1056\/NEJMoa1314258","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis","volume":"144","author":"Krueger JG","year":"2019","unstructured":"Krueger JG, Wharton KA Jr, Schlitt T, et al.. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol. 2019, 144:750-63. 10.1016\/j.jaci.2019.04.029","journal-title":"J Allergy Clin Immunol"},{"key":"ref14","article-title":"Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies","volume":"101","author":"Nakamura M","year":"2018","unstructured":"Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T. Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies. Cutis. 2018, 101:38.","journal-title":"Cutis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.047","article-title":"Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation","volume":"62","author":"Menon K","year":"2010","unstructured":"Menon K, Van Voorhees AS, Bebo BF, et al.. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010, 62:291-9. 10.1016\/j.jaad.2009.03.047","journal-title":"J Am Acad Dermatol"},{"key":"ref16","article-title":"Unraveling the paradoxes of HIV-associated psoriasis: a review of T-cell subsets and cytokine profiles","volume":"13","author":"Fife DJ","year":"2007","unstructured":"Fife DJ, Waller JM, Jeffes EW, Koo JY. Unraveling the paradoxes of HIV-associated psoriasis: a review of T-cell subsets and cytokine profiles. Dermatol Online J. 2007, 13:4.","journal-title":"Dermatol Online J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2022.0197","article-title":"Biologic therapies in HIV\/AIDS patients with inflammatory diseases: a systematic review of the literature","volume":"37","author":"Bang AS","year":"2023","unstructured":"Bang AS, Hakimi M, Tahir P, Bhutani T, Leslie KS. Biologic therapies in HIV\/AIDS patients with inflammatory diseases: a systematic review of the literature. AIDS Patient Care STDS. 2023, 37:215-42. 10.1089\/apc.2022.0197","journal-title":"AIDS Patient Care STDS"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15610","article-title":"Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast","volume":"35","author":"Romita P","year":"2022","unstructured":"Romita P, Foti C, Calianno G, Chiricozzi A. Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast. Dermatol Ther. 2022, 35:e15610. 10.1111\/dth.15610","journal-title":"Dermatol Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S395348","article-title":"Interleukin-17A inhibitor secukinumab treatment in HIV-positive psoriasis patient: a case report","volume":"15","author":"Gong J","year":"2022","unstructured":"Gong J, Wu W, Qiu L, et al.. Interleukin-17A inhibitor secukinumab treatment in HIV-positive psoriasis patient: a case report. Clin Cosmet Investig Dermatol. 2022, 15:2949-56. 10.2147\/CCID.S395348","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.12932\/AP-110521-1129","article-title":"Biological therapy in psoriasis: an emphasis on its dermatologic adverse events","volume":"39","author":"Palakornkitti P","year":"2021","unstructured":"Palakornkitti P, Nimmannitya K, Rattanakaemakorn P. Biological therapy in psoriasis: an emphasis on its dermatologic adverse events. Asian Pac J Allergy Immunol. 2021, 39:215-30. 10.12932\/AP-110521-1129","journal-title":"Asian Pac J Allergy Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/277159-successful-biological-treatment-of-a-patient-with-psoriasis-and-hiv","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T05:43:15Z","timestamp":1729489395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/277159-successful-biological-treatment-of-a-patient-with-psoriasis-and-hiv"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,20]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.71970","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,20]]}}}